<div id="readability-page-1"><p>Orca Wealth Management LLC bought a new position in  Abbott Laboratories (NYSE:ABT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,548 shares of the healthcare product maker's stock, valued at approximately $288,000.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li></ul><p>Other institutional investors and hedge funds also recently bought and sold shares of the company. Bath Savings Trust Co lifted its stake in shares of  Abbott Laboratories by 3.7% during the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock valued at $18,791,000 after buying an additional 5,881 shares in the last quarter.  Simplify Asset Management Inc. boosted its stake in shares of  Abbott Laboratories by 67.3% during the 3rd quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker's stock worth $1,606,000 after purchasing an additional 5,664 shares during the period.  Pensionfund Sabic bought a new position in shares of  Abbott Laboratories during the fourth quarter valued at approximately $2,828,000.  Sequoia Financial Advisors LLC increased its stake in  Abbott Laboratories by 19.6% in the third quarter. Sequoia Financial Advisors LLC now owns 193,764 shares of the healthcare product maker's stock worth $22,091,000 after purchasing an additional 31,720 shares during the period.  Finally, Tidal Investments LLC lifted its holdings in  Abbott Laboratories by 30.5% during the 3rd quarter. Tidal Investments LLC now owns 107,308 shares of the healthcare product maker's stock valued at $12,234,000 after buying an additional 25,052 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of equities analysts have recently issued reports on ABT shares. Morgan Stanley increased their price target on Abbott Laboratories from $107.00 to $117.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, October 17th. Mizuho raised their price target on Abbott Laboratories from $115.00 to $130.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday, October 17th. Barclays  reiterated an &#34;overweight&#34; rating and issued a $158.00 target price (up from $149.00) on shares of Abbott Laboratories in a research note on Monday. Jefferies Financial Group lifted their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, October 17th. Finally, Raymond James  reiterated a &#34;buy&#34; rating and set a $129.00 price objective (up from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and thirteen have assigned  a buy rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average price target of $133.06.</p><ul><li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li></ul><p><b>Check Out Our Latest Analysis on Abbott Laboratories</b></p><h2>Abbott Laboratories Stock Performance</h2><p>NYSE ABT opened at $127.28 on Wednesday. The stock has a 50-day moving average of $115.50 and a 200 day moving average of $113.64. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $129.85. The stock has a market capitalization of $220.76 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.51 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. </p><ul><li>MarketBeat Week in Review – 10/14 - 10/18</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion during the quarter, compared to analysts' expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $1.19 earnings per share.  Sell-side analysts anticipate that  Abbott Laboratories will post 5.15 EPS for the current fiscal year. </p><h2>Abbott Laboratories Increases Dividend</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, January 15th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.85%. Abbott Laboratories's payout ratio is currently 30.85%. </p><h2>Abbott Laboratories Profile</h2> (Free Report)<p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>What Does the Future Hold for Eli Lilly?</li><li>Quiet Period Expirations Explained</li><li>Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Orca Wealth Management LLC acquired a new position in Abbott Laboratories (NYSE:ABT) during the 4th quarter, purchasing 2,548 shares valued at approximately $288,000. Other institutional investors also increased their stakes in Abbott. Analysts have raised price targets for the stock, with an average target of $133.06 and a consensus rating of "Moderate Buy." Abbott's stock opened at $127.28, with a market cap of $220.76 billion. The company recently reported earnings of $1.34 per share and announced a dividend increase to $0.59 per share, payable on February 14th.</p>

Orca Wealth Management LLC Acquires New Position in Abbott Laboratories (NYSE:ABT)